Patent intelligence · US
US 12428389
Diarylamide compound and application thereof
Diarylamide compound and application thereof
Patent details — US 12428389
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 30, 2025
- Expiration
- Sep 25, 2045
- Applicant
- SUNSHINE LAKE PHARMA CO., LTD.
- Claims
- 10
- CPC classes
- A61K, A61K31/167, A61K31/341, A61K31/381
Quick answer
US 12428389 (Diarylamide compound and application thereof) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SUNSHINE LAKE PHARMA CO., LTD.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/167, A61K31/341, A61K31/381, A61K31/40, A61K31/4155
More from SUNSHINE LAKE PHARMA CO., LTD.
Related pharmaceutical patents in our USPTO index.
-
US 12428432
Thienopyrimidine derivatives having stereo configurations and use thereof in medicine
granted -
US 12384853
Anti-HER2/PD1 bispecific antibody
granted -
US 12324812
Glucopyranosyl derivatives and their uses
granted -
US 12319748
Antibody binding to human HER2 and preparation method and use thereof
granted -
US 12312348
RET inhibitors, pharmaceutical compositions and uses thereof
granted -
US 12269886
Tetravalent bispecific antibody against PD-1 and PD-L1
granted -
US 12258317
Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof
granted
Frequently asked questions
What is US patent 12428389?
US 12428389 (Diarylamide compound and application thereof) is held by SUNSHINE LAKE PHARMA CO., LTD.. Status: granted. Granted Sep 30, 2025. Expires Sep 25, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12428389?
SUNSHINE LAKE PHARMA CO., LTD. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 121 pharmaceutical patents for this assignee.
When does US 12428389 expire?
Our index shows an expiration date of Sep 25, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.